Biologic Lung Volume Reduction: Phase II data

In an open-label, U.S. Phase II trial in 22 patients with upper lobe predominant emphysema, 20 mL BLVR hydrogel met the primary endpoint of a statistically significant reduction in lung volume at 3 mo...